Pharma Marketletter - Biovail gets US approval for long-acting Cardizem LA; launch in April.
Sunday, December 28th, 2008Canada’s Biovail has achieved a significant milestone with the US approval of Cardizem LA (diltiazem), the first drug developed under a New Drug Application that the company will launch directly to physicians. Cardizem LA is a graded-release formulation of the calcium channel blocker that provides 24-hour control of blood…
